Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine.

ABSTRACT:

Background

Mesenchymal stromal cells (MSCs) are promising cell therapy candidates. Clinical application is considered safe. However, minor side effects have included thromboembolism and instant blood-mediated inflammatory reactions suggesting an effect of MSC infusion on hemostasis. Previous studies focusing on plasmatic coagulation as a secondary hemostasis step detected both procoagulatory and anticoagulatory activities of MSCs. We now focus on primary hemostasis and analyzed whether MSCs can promote or inhibit platelet activation.

Methods

Effects of MSCs and MSC supernatant on platelet activation and function were studied using flow cytometry and further platelet function analyses. MSCs from bone marrow (BM), lipoaspirate (LA) and cord blood (CB) were compared to human um

SUBMITTER: Netsch P 

PROVIDER: S-EPMC6033237 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature